SEARCH

SEARCH BY CITATION

  • 1
    Travis WD, Linder J, Mackay B. Classification, histology, cytology, and electron microscopy. In: PassH, MitchellJB, JohnsonDH, TurrisiAT, editors. Lung cancer: principles and practice. Philadelphia : Lippincott-Raven, 1996. p. 36196.
  • 2
    Barkley JE, Green MR. Bronchioloalveolar carcinoma. J Clin Oncol 1996; 14: 237786.
  • 3
    Homma S, Kawabata M, Kishi K, Tsuboi E, Narui K, Nakatani T, Nakata K. Successful treatment of refractory bronchorrhea by inhaled indomethacin in two patients with bronchioloalveolar carcinoma. Chest 1999; 115: 14658.
  • 4
    van Zandwijk N, Jassem E, Dubbelmann R, Braat MC, Rumke P. Aerosol application of interferon-alpha in the treatment of bronchioloalveolar carcinoma. Eur J Cancer 1990; 26: 73840.
  • 5
    Yano T, Ichinose Y, Yokoyama H, Fukuyama Y, Sugio K, Sugimachi K. Inhalation therapy using a streptococcal preparation (OK-432) against bron-chioloalveloar carcinoma of the lung. Anticancer Res 1999; 19: 55114.
  • 6
    Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA Jr. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 2002; 29 Suppl 4: 3746.
  • 7
    Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J-Y, Nishiwaki Y, Vansteenkiste J, Kudo S, Averbuch S, Macleod A, Feyereislova A, Baselga J. Final results from a phase II trial of ZD1839 (“Iressa”) for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 2002; 21: 298a (abstract 1188).
  • 8
    Douillard J-Y, Giaccone G, Horai T, Noda K, Vansteenkiste JF, Takata I, Gatzemeier U, Fukuoka M, Macleod A, Feyereislova A, Averbuch S, Nogi Y, Heyers A, Baselga J. Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD1839 (“Iressa”) (IDEAL 1). Proc Am Soc Clin Oncol 2002; 21: 299a (abstract 1195).
  • 9
    Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis C, Albain KS, Brahmer JR, Sandier A, Crawford J, Lutzker SG, Lilenbaum R, Helms L, Wolf M, Averbuch S, Ochs J, Kay A. A phase II trial of ZD1839 (“Iressa”) in advanced non-small-cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002; 21: 292a (abstract 1166).
  • 10
    Natale RR, Skarin AT, Maddox A, Hammond LA, Thomas R, Gandara DR, Gerstein H, Panella T, Cole J, Jahanzeb M, Kash J, Hamm J, Langer C, Saleh M, Stella P, Heyes A, Helms L, Ochs J, Averbuch S, Wolf M, Kay A. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients recieving ZD1839 (“Iressa”) in IDEAL 2. Proc Am Soc Clin Oncol 2002; 21: 292a (abstract 1167).
  • 11
    Takeyama K, Dabbagh K, Lee HM, Agusti C, Lausier JA, Ueki IF, Grattan KM, Nadel JA. Epidermal growth factor system regulates mucin production in airways. Proc Natl Acad Sci USA 1999; 96: 30816.
  • 12
    Takeyama K, Fahy JV, Nadel JA. Relationship of epidermal growth factor receptors to goblet cell production in human bronchi. Am J Respir Crit Care Med 2001; 163: 5116.
  • 13
    Klein JM, McCarthy TA, Dagle JM, Snyder JM. Antisense inhibition of epidermal growth factor receptor decreases expression of human surfactant protein A. Am J Respir Cell Mol Biol 2000; 22: 67684.
  • 14
    Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001; 61: 71848.